2026 Interim report
Filed with HKEX · Stock code 1167 · · 77 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue driven by strategic collaborations and licensing agreements. Additionally, the company reported a profit for the reporting period, contrasting with a loss in the previous year, showcasing improved financial performance. The report also outlines advancements in their drug pipeline, including progress on key products and ongoing clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Jacobio Pharmaceuticals Group Co., Ltd. on 6ix
Earlier from Jacobio Pharmaceuticals
- Jacobio Announces 2025 Annual Results
- Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
- Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
- Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
- Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
Later from Jacobio Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Follow Jacobio Pharmaceuticals into a list and get an email when it puts out news.
Follow Jacobio Pharmaceuticals